Abstract
Transient receptor potential (TRP) channels are important candidates mediating Ca2+ influx in excitable and nonexcitable cells such as normal and neoplastic hematopoietic tissues. They are non selective cation channels implicated in Ca2+ signaling in hematologic tumor cells. Here, we review the growing experimental evidence indicating that TRP channels should be included among the genes whose expression is altered in hematologic malignancies such as leukemias (AML, ALL, CML and CLL), B- and T-lymphomas and multiple myelomas (MM). These effects depend on the widespread roles played by the TRP channels in the modulation of the proliferation, differentiation and apoptosis of the hematopoietic cells. The analysis of the expression of the different TRP channels belonging to the TRPMs, TRPVs, TRPCs, TRPPs channel families expressed in different hematological malignacies, evidenced a widespread expression of TRPV2 channel in the myeloid and lymphoid leukemias, and a very peculiar expression of this channel in different types of B cell lymphomas and multiple myeloma, that is parallel to the restricted expression of TRPV2 in normal immune cells with respect to its presence in other human tissues. In vivo studies in children AML and ALL patients also evidenced the presence of a genetic polymorphism of the TRPM5 gene, that reduced the risk to develop leukemia in the children. Finally, the coexpression of TRPV5 and TRPV6 channels in lymphocytes, and their involvement in the radioresistance of K562 erythroleukemia cells to ionizing radiation exposure is of more interest.
Thus in conclusion, the TRP channels represent promising targets for hematologic cancer therapy, and their exploitation may open to novel pharmaceutical and clinical approaches.
Keywords: Hematologic malignancies, ion channels, leukemia, lymphoma, multiple myeloma, transient receptor potential channel family.
Current Molecular Pharmacology
Title:Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies
Volume: 6
Author(s): Maria B. Morelli, Sonia Liberati, Consuelo Amantini, Massimo Nabiss, Matteo Santoni, Valerio Farfariello and Giorgio Santoni
Affiliation:
Keywords: Hematologic malignancies, ion channels, leukemia, lymphoma, multiple myeloma, transient receptor potential channel family.
Abstract: Transient receptor potential (TRP) channels are important candidates mediating Ca2+ influx in excitable and nonexcitable cells such as normal and neoplastic hematopoietic tissues. They are non selective cation channels implicated in Ca2+ signaling in hematologic tumor cells. Here, we review the growing experimental evidence indicating that TRP channels should be included among the genes whose expression is altered in hematologic malignancies such as leukemias (AML, ALL, CML and CLL), B- and T-lymphomas and multiple myelomas (MM). These effects depend on the widespread roles played by the TRP channels in the modulation of the proliferation, differentiation and apoptosis of the hematopoietic cells. The analysis of the expression of the different TRP channels belonging to the TRPMs, TRPVs, TRPCs, TRPPs channel families expressed in different hematological malignacies, evidenced a widespread expression of TRPV2 channel in the myeloid and lymphoid leukemias, and a very peculiar expression of this channel in different types of B cell lymphomas and multiple myeloma, that is parallel to the restricted expression of TRPV2 in normal immune cells with respect to its presence in other human tissues. In vivo studies in children AML and ALL patients also evidenced the presence of a genetic polymorphism of the TRPM5 gene, that reduced the risk to develop leukemia in the children. Finally, the coexpression of TRPV5 and TRPV6 channels in lymphocytes, and their involvement in the radioresistance of K562 erythroleukemia cells to ionizing radiation exposure is of more interest.
Thus in conclusion, the TRP channels represent promising targets for hematologic cancer therapy, and their exploitation may open to novel pharmaceutical and clinical approaches.
Export Options
About this article
Cite this article as:
Morelli B. Maria, Liberati Sonia, Amantini Consuelo, Nabiss Massimo, Santoni Matteo, Farfariello Valerio and Santoni Giorgio, Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies, Current Molecular Pharmacology 2013; 6 (3) . https://dx.doi.org/10.2174/187446720603140415215431
DOI https://dx.doi.org/10.2174/187446720603140415215431 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
Call for Papers in Thematic Issues
Advances in the Diagnosis and Treatment of Head and Neck Disease
Head and neck diseases encompass a wide range of conditions affecting the oral cavity, pharynx, larynx, nasal passages, sinuses, salivary glands, and other structures of the head and neck region. These diseases can have significantly on essential function, such as breathing, swallowing, speaking, as well as the quality of life. ...read more
Common Mechanisms Underpinning Neurodevelopmental Disorders and Psychiatric Diseases
A growing number of large-scale epidemiologic studies have strongly suggested that common mechanisms may be shared by aberrant brain development and psychiatric disorders. There is now an appreciation of the synergic roles of genetic variants and environmental stress, which profoundly affect genome integrity and reshape brain development. This can lead ...read more
New Cell Death Regulation Drugs for Cardiovascular Diseases
Cardiovascular diseases are the leading cause of mortality worldwide, with aberrant cell death processes playing a crucial role in their pathogenesis. Cell death in these diseases encompasses not only well-studied forms of apoptosis but also includes a variety of complex modes such as mitochondrial permeability transition (MPT)-driven necrosis, entotic cell ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer
Target by Manumycin-related Natural Products
Current Medicinal Chemistry Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Effects of Ascorbic Acid on Tax, NF-κB and MMP-9 in Human T-cell Lymphotropic Virus Type 1 Positive Malignant T-Lymphocytes
Anti-Cancer Agents in Medicinal Chemistry Gene Selection from Microarray Data Using Binary Grey Wolf Algorithm for Classifying Acute Leukemia
Current Signal Transduction Therapy Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Adipose Tissue-Mesenchymal Stem Cells Caused to Change the Methylation Status of <i>hTERT</i> Gene Promoter CpG Islands of Molt-4 Leukemia Cells as Cell-based Therapy
Current Molecular Medicine Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Design of Nanodrug Delivery Systems for Tumor Bone Metastasis
Current Pharmaceutical Design Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Angiogenesis in the Treatment of Multiple
Current Angiogenesis (Discontinued) Fungal Infection in Cystic Fibrosis
Current Respiratory Medicine Reviews Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy
Current Cardiology Reviews